Standard Chemical & Pharmaceutical Co., Ltd. (TPE:1720)
56.00
+0.10 (0.18%)
Aug 19, 2026, 1:30 PM CST
TPE:1720 Revenue
Standard Chemical & Pharmaceutical had revenue of 1.87B TWD in the quarter ending June 30, 2026, with 2.44% growth. This brings the company's revenue in the last twelve months to 7.08B, up 2.85% year-over-year. In the year 2025, Standard Chemical & Pharmaceutical had annual revenue of 7.02B with 3.44% growth.
Revenue (ttm)
7.08B
Revenue Growth
+2.85%
P/S Ratio
1.55
Revenue / Employee
n/a
Employees
n/a
Market Cap
10.99B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.02B | 233.80M | 3.44% |
| Dec 31, 2024 | 6.79B | 549.46M | 8.81% |
| Dec 31, 2023 | 6.24B | 388.40M | 6.64% |
| Dec 31, 2022 | 5.85B | 1.25B | 27.09% |
| Dec 31, 2021 | 4.60B | 298.68M | 6.94% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Grape King Bio | 10.28B |
| YungShin Global Holding | 7.84B |
| TTY Biopharm Company | 6.65B |
| Synmosa Biopharma | 6.37B |
| Formosa Laboratories | 4.64B |
| ScinoPharm Taiwan | 3.07B |
| Handa Pharmaceuticals | 1.76B |
| Orient Pharma | 1.52B |